Abstract:James P Franciosi, 1, 2 Edward B Mougey, 3 Evan S Dellon, 4 Carolina Gutierrez-Junquera, 5 Sonia Fernandez-Fernandez, 6 Rajitha D Venkatesh, 7 Sandeep K Gupta 8 1 Division of Gastroenterology, Nemours Children's Hospital, Orlando, FL, USA; 2 College of Medicine, University of Central Florida, Orlando, FL, USA; 3 Center for Pharmacogenomics and Translational Research, Nemours Children's Health System, Jacksonville, FL, USA; 4 Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; 5 Pediatric Gastroenterology Unit, Hospital Universitario Puerta de Hierro-Majadahonda, Autonomous University of Madrid, Madrid, Spain; 6 Pediatric Gastroenterology Unit, Hospital Universitario Severo Ochoa, Madrid, Spain; 7 Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, OH, USA; 8 Section of Pediatric Gastroenterology, Hepatology and Nutrition, Riley Hospital for Children, Indiana University School of Medicine and Community Health Network, Indianapolis, IN, USA Correspondence: James P Franciosi, Division of Gastroenterology, Nemours Children's Hospital, 6535 Nemours Parkway, Orlando, FL, 32827, USA, Tel +1 407 567 3832 ; +1 407 335 9908, Email Over the past decade, the role of proton pump inhibitor (PPI) medication has evolved from a diagnostic tool for Eosinophilic Esophagitis (EoE), by excluding patients with PPI responsive esophageal eosinophilia (PPI-REE), to a therapy for EoE. This transition resulted from the Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the Appraisal of Guidelines for Research and Evaluation II (AGREE) Conference to support PPI therapy for EoE in children and adults. Additional recent advances have suggested a role for genetic variations that might impact response to PPI therapy for EoE. This review article will explore a brief background of EoE, the evolution of PPI therapy for EoE and its proposed mechanisms, efficacy and safety in children and adults, and considerations for future PPI precision medicine in patients with EoE. Keywords: eosinophilic esophagitis, EoE, proton pump inhibitor medication, PPI, precision medicine EoE is a chronic antigen-mediated inflammatory disease of the esophagus that affects both children and adults (Figure 1). 4 It is a clinicopathologic disorder requiring a constellation of clinical and histologic findings (at least 15 eosinophils/high-powered microscope field (eos/hpf)) to establish the diagnosis, while excluding other etiologies of esophageal eosinophilia. 1 The incidence and prevalence of EoE are rapidly rising as described in several population-based studies from the United States and Europe with an estimated incidence of 6.6 per 100,000 person-years (95% CI, 3–11.7) in children and 7.7 per 100,000 person-years (95% CI, 1.8–17.8) in adults. 5 Esophageal dysfunction in EoE may present differently in children and adults. Infants and young children typically present with feeding difficulty, poor growth, abdominal pain, and vomiting while older children and adults present with dysphagia and esophageal food impaction. Patients with EoE may have a personal history of atopic conditions such as asthma, allergic rhinitis, allergic conjunctivitis and IgE mediated food allergies. Although EoE does not demonstrate classic Mendelian inheritance, there can be a genetic component to the condition in some patients, and a familial history of EoE increases individual risk compared to the general population. 6 Inflammation in EoE is thought to result from penetration of the esophageal mucosa by food or aeroantigens resulting in a T-helper type 2 (T h 2) cellular response and symptoms of esophageal dysfunction. 7 Figure 1 Eosinophilic esophagitis: clinical & pathophysiologic overview. Notes : Top Left: Major known environmental triggers of EoE include most commonly food allergens (ie, dairy, wheat, egg, soy and legumes) and to a lesser extent, aeroallergens (eg, pollen). Recently, a role for the gut microbiome in inception and/or severity of EoE has been proposed. 209 Middle Left: EoE symptoms by age group. Bottom left: The three main classes of EoE therapies: 1.) diet modification, ie, elimination diets; 2.) medications including proton pump inhibitors, topical swallowed corticosteroids, and biologics; 3.) endoscopic dilation. Upper right: EoE pathophysiology current understanding. A breach in the integrity of the esophageal epithelium, potentially facilitated by gastric acid exposure and/or carriage -Abstract Truncated-

Omeprazole-Associated Atypical Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in a Patient with Positive In Vitro Diagnostic Testing to Multiple Proton Pump Inhibitors

Identification of novel signal of proton pump inhibitor-associated drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis

Drug Rash with Eosinophilia and Systemic Symptoms and Severe Renal Injury Induced by Proton Pump Inhibitor Therapy: A Case Report.

S3392 Rash Decisions: An Unexpected Consequence of PPI Use

Atypical Presentation of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: When Gastrointestinal Symptoms Obscure the Diagnosis

Antipsychotics Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Literature Review and a Report of a Suspected Case Related to Chlorpromazine

PSUN62 A Rare Case of Atorvastatin Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome - A Case Report.

Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis

Less Known Gastrointestinal Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review of the Literature

The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H2 Receptor Antagonists with Clinical Complications in Patients with Severe Sepsis

Allergic phenotype identified on allergen testing is associated with proton pump inhibitor nonresponse in eosinophilic esophagitis

DRESS Syndrome: Renal Involvement in Two Cases - A Comprehensive Analysis and Literature Review of Improved Diagnosis and Treatment

Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms

Proton pump inhibitor alters Th17/Treg balance and induces gut dysbiosis suppressing contact hypersensitivity reaction in mice

Digestive Tract Cancer Related Adverse Events Associated with Proton Pump Inhibitors use: A Pharmacovigilance Study of the FDA Adverse Event Reporting System

Histopathologic Features of Drug Reaction With Eosinophilia and Systemic Symptoms

Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions

Phloroglucinol-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome with Subsequent Fulminant Type 1 Diabetes (FT1D): A Rare Case and Literature Review

Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Due to Multiple Anti-Epileptic Drug Hypersensitivity

Drug reaction with eosinophilia and systemic symptoms: An update and review of recent literature

Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study